The role of Wilms' tumor gene peptide-specific cytotoxic T lymphocytes in immunologic selection of a paroxysmal nocturnal hemoglobinuria clone

Experimental Hematology

Volumn 35, Issue 4, 2007, Pages 618-626

  Ikeda, Kazuhiko ^a   Shichishima, Tsutomu ^a,b   Yasukawa, Masaki ^c   Nakamura Shichishima, Akiko ^a   Noji, Hideyoshi ^a   Akutsu, Kazuko ^a   Osumi, Kazuoki ^d   Maruyama, Yukio ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b Fukushima Research Institute of Environment and Medicine   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Otsuka Life Science Initiative   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD; BONE MARROW CELL; CD34 SELECTION; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE FREQUENCY; HUMAN; HUMAN CELL; IMMUNOLOGY; MALE; MOLECULAR CLONING; MONONUCLEAR CELL; NEPHROBLASTOMA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL;

ADULT; ALLELES; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, WILMS TUMOR; HEMOGLOBINURIA, PAROXYSMAL; HLA-A ANTIGENS; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33947279545     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.01.045     Document Type: Article

References (47)

1. Rosse W.F., and Parker C.J. Paroxysmal nocturnal haemoglobinuria. Clin Haematol 14 (1985) 105-125
2. Hillmen P., Lewis S.M., Bessler M., Luzzatto L., and Dacie J.V. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 333 (1995) 1253-1258
3. Parker C., Omine M., Richards S., et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106 (2005) 3699-3709
4. Young N.S. The problem of clonality in aplastic anemia: Dr. Dameshek's riddle, restated. Blood 79 (1992) 1385-1392
5. Nicholson-Weller A., March J.P., Rosenfeld S.I., and Austen K.F. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A 80 (1983) 5066-5070
6. Shichishima T., Terasawa T., Hashimoto C., Ohto H., Uchida T., and Maruyama Y. Heterogeneous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes. Br J Haematol 78 (1991) 545-550
7. Takeda J., Miyata T., Kawagoe K., et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73 (1993) 703-711
8. Kawagoe K., Kitamura D., Okabe M., et al. Glycosylphosphatidylinositol-anchor-deficient mice: implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria. Blood 87 (1996) 3600-3606
9. Yamamoto T., Shichishima T., Shikama Y., Saitoh Y., Ogawa K., and Maruyama Y. Granulocytes from patients with paroxysmal nocturnal hemoglobinuria and normal individuals have the same sensitivity to spontaneous apoptosis. Exp Hematol 30 (2002) 187-194
10. Kulkarni S., and Bessler M. The effect of GPI-anchor deficiency on apoptosis in mice carrying a Piga gene mutation in hematopoietic cells. J Leukoc Biol 72 (2002) 1228-1233
11. Nakao S., Takamatsu H., Chuhjo T., et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood 84 (1994) 4257-4261
12. Maciejewski J.P., Follmann D., Nakamura R., et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 98 (2001) 3513-3519
13. Shichishima T., Okamoto M., Ikeda K., et al. HLA class II haplotype and quantitation of WT1 RNA in Japanese patients with paroxysmal nocturnal hemoglobinuria. Blood 100 (2002) 22-28
14. Okamoto M., Shichishima T., Noji H., et al. High frequency of several PIG-A mutations in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 20 (2006) 627-634
15. Shichishima T., Noji H., Ikeda K., Akutsu K., and Maruyama Y. The frequency of HLA class I alleles in Japanese patients with bone marrow failure. Haematologica 91 (2006) 856-857
16. Zeng W., Maciejewski J.P., Chen G., and Young N.S. Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest 108 (2001) 765-773
17. Plasilova M., Risitano A.M., O'Keefe C.L., et al. Shared and individual specificities of immunodominant cytotoxic T-cell clones in paroxysmal nocturnal hemoglobinuria as determined by molecular analysis. Exp Hematol 32 (2004) 261-269
18. Nakao S., Yamaguchi M., Shiobara S., et al. Interferon-gamma gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia. Blood 79 (1992) 2532-2535
19. Luzzatto L., and Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 3 (1996) 101-110
20. Young N.S., and Maciejewski J.P. Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes "Why? Why? Why?". J Clin Invest 106 (2000) 637-641
21. Karadimitris A., Notaro R., Koehne G., Roberts I.A., and Luzzatto L. PNH cells are as sensitive to T-cell-mediated lysis as their normal counterparts: implications for the pathogenesis of paroxysmal nocturnal haemoglobinuria. Br J Haematol 111 (2000) 1158-1163
22. Kai T., Shichishima T., Noji H., et al. Phenotypes and phosphatidylinositol glycan-class A gene abnormalities during cell differentiation and maturation from precursor cells to mature granulocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood 100 (2002) 3812-3818
23. Oka Y., Elisseeva O.A., Tsuboi A., et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 51 (2000) 99-107
24. + cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95 (2000) 286-293
25. Koesters R., Linnebacher M., Coy J.F., et al. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int J Cancer 109 (2004) 385-392
26. Doubrovina E.S., Doubrovin M.M., Lee S., et al. In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity. Clin Cancer Res 10 (2004) 7207-7219
27. Tamaki H., Ogawa H., Ohyashiki K., et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13 (1999) 393-399
28. Inoue K., Sugiyama H., Ogawa H., et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84 (1994) 3071-3079
29. Lyakisheva A., Felda O., Ganser A., Schmidt R.E., and Schubert J. Paroxysmal nocturnal hemoglobinuria: Differential gene expression of EGR-1 and TAXREB107. Exp Hematol 30 (2002) 18-25
30. Heeney M.M., Ormsbee S.M., Moody M.A., Howard T.A., DeCastro C.M., and Ware R.E. Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria. Mol Genet Metab 78 (2003) 291-294
31. Inoue N., Murakami Y., and Kinoshita T. Molecular genetics of paroxysmal nocturnal hemoglobinuria. Int J Hematol 77 (2003) 107-112
32. Tsuji T., Yasukawa M., Matsuzaki J., et al. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood 106 (2005) 470-476
33. Shichishima T., Terasawa T., Saitoh Y., Hashimoto C., Ohto H., and Maruyama Y. Diagnosis of paroxysmal nocturnal haemoglobinuria by phenotypic analysis of erythrocytes using two-colour flow cytometry with monoclonal antibodies to DAF and CD59/MACIF. Br J Haematol 85 (1993) 378-386
34. Lewis S.M., and Dacie J.V. The aplastic anaemia-paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol 13 (1967) 236-251
35. Sugita Y., Nakano Y., and Tomita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem 104 (1988) 633-637
36. Shichishima T., Terasawa T., Uchida T., and Kariyone S. Complement sensitivity of erythroblasts and erythropoietic precursors in paroxysmal nocturnal haemoglobinuria (PNH). Br J Haematol 72 (1989) 578-583
37. Altman J.D., Moss P.A., Goulder P.J., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 (1996) 94-96
38. Bodinier M., Peyrat M.A., Tournay C., et al. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nat Med 6 (2000) 707-710
39. Karanikas V., Lurquin C., Colau D., et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant Canarypox virus. J Immunol 171 (2003) 4898-4904
40. + T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102 (2003) 2892-2900
41. *0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 11 (2005) 8799-8807
42. Azuma T., Otsuki T., Kuzushima K., Froelich C.J., Fujita S., and Yasukawa M. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 10 (2004) 7402-7412
43. Scheibenbogen C., Letsch A., Thiel E., et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100 (2002) 2132-2137
44. Amrolia P.J., Reid S.D., Gao L., et al. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 101 (2003) 1007-1014
45. Elisseeva O.A., Oka Y., Tsuboi A., et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99 (2002) 3272-3279
46. Howe E.C., Wlodarski M., Ball E.J., Rybicki L., and Maciejewski J.P. Killer immunoglobulin-like receptor genotype in immune-mediated bone marrow failure syndromes. Exp Hematol 33 (2005) 1357-1362
47. Sugiyama H. Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 73 (2001) 177-187